| INTRODUCTION
Congenital disorders of glycosylation (CDG) are a group of inherited diseases characterized by defective glycosylation of proteins and lipids. The most common subtype of CDG is PMM2-CDG, which is recessively inherited. Mutations in PMM2 cause reduced activity of phosphomannomutase (PMM), which is the enzyme that converts mannose 6-phosphate to mannose 1-phosphate. This causes disturbed dolichol-oligosaccharide synthesis and eventually leads to hypoglycosylation of glycoproteins (Van & Jaeken, 1995) .
The clinical phenotype of PMM2-CDG ranges from mild to severe.
It can affect many organs and usually involves the central nervous system. During infancy, PMM2-CDG often presents with inverted nipples, fat pads, strabismus, axial hypotonia, and hyporeflexia.
Severely affected patients also have visceral symptoms in addition to severe intellectual disability (ID) and other neurological findings.
Mortality is around 20% in the first years of life (Hagberg, Blennow, Kristiansson, & Stibler, 1993; Kjaergaard, Schwartz, & Skovby, 2001) .
In rare patients, a much milder clinical presentation is described, where strabismus, hypotonia, cerebellar hypoplasia, mild-to-moderate ID, and higher residual PMM2 activity in fibroblasts are seen; whereas dysmorphic features, epilepsy, and stroke-like episodes are much less frequent (Barone et al., 2015; Grunewald, Schollen, Van Schaftingen, Jaeken, & Matthijs, 2001 ).
Here, we report six patients of three families from Estonia, the Netherlands, and the United States, who have clinically very mild PMM2-CDG with normal cognitive development.
In family A (Table 1) , the parents of the siblings are non-consanguineous, and all children were born at term after an uncomplicated pregnancy and delivery. PMM2-CDG was first diagnosed in the youngest sibling (A1) at the age of 10 months. She presented with delayed motor skills, muscular hypotonia, truncal ataxia, and strabismus. She was not crawling and sat insecurely. However, her cognitive development and growth parameters were appropriate for her age. She started to walk independently at the age of 21 months.
Two older siblings (proband A2 and A3 in Table 1 ) also had problems with gross motor development, and ataxia in infancy and early childhood. A2 started to walk at 19 months of age and his speech development was delayed, whereas A3 started to walk at 21 months of age, but had no problems with speech development. Brain MRI of probands A2 and A3 showed non-progressive cerebellar hypoplasia.
All sibs have needed orthodontic treatment, since they continued to have an infantile swallowing pattern characterized by tongue thrusting, which caused occlusion abnormalities. All probands showed some coagulation abnormalities, and females need to be followed for the risk of developing hypergonadotropic hypogonadism (details in Table 1 ).
According to the Wechsler Intelligence Scale for Children (WISC), the full scale IQ scores were 72 and 81 for probands A2 and A3, at the ages of 16 and 8, respectively. Proband A3 compensated for his borderline IQ with good working memory (index 97). Both older sibs presently study in normal school.
| Family B
In family B (Table 1) , both children were born to non-consanguineous parents at term after an uneventful pregnancy. PMM2-CDG was first diagnosed in the oldest sibling (B1) at the age of 10 years, when she presented with mildly delayed motor skills and hypothyroidism. She started to walk at the age of 20 months. At the age of 16 years she was evaluated for delayed puberty. She attended normal education and finished secondary school. She was diagnosed with anxiety and autistic features, although her communication skills were normal. Her older brother (B2) had a similar mild motor developmental delay as well as strabismus. He had delayed speech development and mild dysarthria.
He attended special education for his speech impediment, which normalized at the age of 14 years. There were no coagulation abnormalities or abnormal liver function tests in patients in family B.
WISC showed that proband B1 has full scale IQ score of 93 and proband B2 an IQ score of 72.
| Family C
In family C (Table 1) , the patient C1 was born at term to nonconsanguineous parents after an uneventful pregnancy. PMM2-CDG was diagnosed at the age of 1 year due to delayed motor skills and ataxia, strabismus and failure to thrive. The patient started to walk at the age of 5 years. She also had dysarthria, but used sentences from the age of two years. A brain MRI showed cerebellar and vermis hypoplasia. There were mild coagulation abnormalities, but no endocrine dysfunction or abnormalities of liver function. She is attending normal education and finished primary school. WISC showed an IQ score of 89.
| METHODS AND RESULTS
All probands from families A, B, and C showed a clear type 1 pattern on serum transferrin isoelectric focusing. (Matthijs et al., 1997; Matthijs, Schollen, Heykants, & Grunewald, 1999) in family B, and c.359T>C (p.Ile120Thr), c.682G>T (p.Gly228Cys) (Matthijs et al., 1999 (Matthijs et al., , 2000 in Family C.
All mutations in
Enzymatic analysis of PMM showed a residual activity of PMM in skin fibroblasts 1.6 mU/mg protein (normal limits 4.7-9.2) in A2 and 2.8 mU/mg protein (normal limits 6.7-11.2) in B1. PMM activity was not measured in patient C1. (Giurgea, Michel, Le Merrer, Seta, & de Lonlay, 2005; Mader, Dobler-Neumann, Kuker, Stibler, & Krageloh-Mann, 2002; Vermeer et al., 2007) . In our report, WISC was performed for five patients, all of whom showed normal cognitive development with full scale IQ ranging from borderline to average (score 72-93).
As in other patients with mild PMM2-CDG, delayed gross motor skills were common among the patients described in this study. Cerebellar hypoplasia was present in all patients in whom brain MRI was performed. clinical symptoms are on the milder end of PMM2-CDG phenotypic spectrum as was described by Grunewald et al. (2001) .
We did not see any difference on serum transferrin isoelectric focusing between severe and mild PMM2-CDG patients, as all six patients showed a clear type 1 pattern despite their mild phenotype and age at the time of diagnosis.
Genotype-phenotype correlation studies in PMM2-CDG patients (Barone et al., 2015; Grunewald et al., 2001 ) have been published.
Some mutations (e.g., H218L, L32R, C241S, T237M) cause a milder phenotype; however, the severity might also depend on the combination of particular mutations (Barone et al., 2015; Matthijs et al., 1999) . In this paper, all reported families had different compound heterozygous mutations. Siblings from family A shared the genotype p.Val231Met/p.Arg239Trp. p.Val231Met is rather frequently found among patients with PMM2-CDG, and its usual combination with the most common mutation, p.Arg141His, has been shown to cause a severe clinical picture (Barone et al., 2015; Grunewald et al., 2001; Matthijs et al., 1997 Matthijs et al., , 2000 . p.Arg239Trp has been described only once in combination with p.Phe157Ser, in which case the patients had either a mild-moderate or a moderate phenotype (Grunewald et al., 2001 ).
Siblings from family B with a common combination of mutations p.Cys241Ser and p.Arg141His support the genotype-phenotype correlation described in other papers, as this genotype has been reported to cause a mild clinical expression (Barone et al., 2015; Giurgea et al., 2005; Grunewald et al., 2001) . Sibling C1 had mutations p.Ile120Thr/p.Gly228Cys. p.Gly228Cys has been described in combination with p. Arg141His in a 4-year-old patient with similar neurological findings and good developmental progress, but also with a cerebral hemorrhage (Stefanits, Konstantopoulou, Kuess, Milenkovic, & Matula, 2014 There is no official management protocol for PMM2-CDG, and the treatment remains supportive and symptomatic. Reviews about hypothyroidism and thrombotic events due to coagulopathy among PMM2-CDG patients have been published, which give suggestions about the management of these conditions (Linssen, Mohamed, Wevers, Lefeber, & Morava, 2013; Mohamed et al., 2012) . All our described patients are under regular follow-up and treated when needed.
We present six patients from three families, who are diagnosed with clinically mild PMM2-CDG and normal cognitive development.
Four out of our six patients were diagnosed with PMM2-CDG at the age of 8 years or later, as their clinical course and neurological symptoms were quite mild and non-progressive, and they were able to participate in regular school programs. This suggests that some of the mild cases of PMM2-CDG might be missed, leading to underdiagnosis of PMM2-CDG. Hence, we encourage screening for CDG among patients with a subtle neurological syndrome and normal cognitive development.
